Impact of the iWHELD digital person‐centered care program on quality of life, agitation and psychotropic medications in people with dementia living in nursing homes during the COVID‐19 pandemic: A randomized controlled trial
INTRODUCTION iWHELD is a digital person‐centered care program for people with dementia in nursing homes adapted for remote delivery during the COVID‐19 pandemic. METHODS A 16‐week two‐arm cluster‐randomized controlled trial in 149 UK nursing homes compared iWHELD with treatment as usual (TAU). Prima...
Gespeichert in:
| Veröffentlicht in: | ALZHEIMERS & DEMENTIA 2024-03, Vol.20 (3), p.1797-1806 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1806 |
|---|---|
| container_issue | 3 |
| container_start_page | 1797 |
| container_title | ALZHEIMERS & DEMENTIA |
| container_volume | 20 |
| creator | McDermid, Joanne Henley, William Corbett, Anne Williams, Gareth Fossey, Jane Clare, Linda Fox, Chris Aarsland, Dag Khan, Zunera Soto, Maria Woodward‐Carlton, Barbara Cook, Esme Moniz Cummings, Jeffrey Sweetnam, Adrienne Chan, Xavier Lawrence, Megan Ballard, Clive |
| description | INTRODUCTION
iWHELD is a digital person‐centered care program for people with dementia in nursing homes adapted for remote delivery during the COVID‐19 pandemic.
METHODS
A 16‐week two‐arm cluster‐randomized controlled trial in 149 UK nursing homes compared iWHELD with treatment as usual (TAU). Primary outcome was the overall quality of life with secondary outcomes of agitation and psychotropic use.
RESULTS
iWHELD conferred benefit to quality of life on the primary (F = 4.3, p = 0.04) and secondary measures of quality of life (F = 6.45, p = 0.01) and reduced psychotropic medication use (χ2 = 4.08, p = 0.04) with no worsening of agitation. Benefit was seen in participants who contracted COVID‐19, those with agitation at baseline, and those taking psychotropic medications.
DISCUSSION
iWHELD confers benefits to quality of life and key measures of well‐being, can be delivered during the challenging conditions of a pandemic, and should be considered for use alongside any emerging pharmacological treatment for neuropsychiatric symptoms.
Highlights
iWHELD is the only remote, digital delivery nursing home training programme for dementia care
iWHELD improved quality of life in people with dementia and reduced antipsychotic use without worsening of agitation
Residents who contracted Covid‐19 during the study also experienced benefits from iWHELD
iWHELD offers a valuable, pandemic‐safe tool for improving dementia care |
| doi_str_mv | 10.1002/alz.13582 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_840011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3089864315</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4422-d0b463c4bd85425630bc861d4d2b63d042c2232a48a2cc2ec8084cc7a9bd47663</originalsourceid><addsrcrecordid>eNp1Us1uEzEYXCEQLYUDL4AscQGJtLbXu_FyQVFaaKRIvfAjcbG89pfExWtv7d1G6YlH4BkRD4K3SaMWidPOeuabGX36suwlwccEY3oi7c0xyQtOH2WHpCjoqKDj6vEel_ggexbjJcYMc1I8zQ5yTkhZkfIw-zNrWqk65BeoWwEy387P5qdIm6XppEUthOjd75-_FLgOAmikZADUBr8MskHeoateWtNthnlrFvAOyWGyM4mSTqM2btTKd8G3RqEGtFG3XETGJXPfWkBr062QhiYlGJlMro1bDrTrQxzgyjcQke7D8DN0nF58nZ2mTqRCbcqAxqj3aIJCwr4xN0NJ71KktQl2wUj7PHuykDbCi933KPvy8ezz9Hw0v_g0m07mI8UYpSONa1bmitWaF4wWZY5rxUuimaZ1mWvMqKI0p5JxSZWioDjmTKmxrGrNxmWZH2WjrW9cQ9vXog2mkWEjvDRi9_QjIRCcYUxI0n_Y6hOTljMsOUj7YOwh48xKLP21ILjirMA0ObzZOQR_1UPsRGOiAmulA99HQSvMSDGuqiHs9T_SS98Hl_YhcswrXrKcFEn1dqtSwccYYLFvQ7AYjk2kYxO3x5a0r-7X3yvvrisJTraCtbGw-b-TmMy_by3_Aga75V4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3089864315</pqid></control><display><type>article</type><title>Impact of the iWHELD digital person‐centered care program on quality of life, agitation and psychotropic medications in people with dementia living in nursing homes during the COVID‐19 pandemic: A randomized controlled trial</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>Wiley Online Library Journals Frontfile Complete</source><source>PubMed Central</source><source>SWEPUB Freely available online</source><source>PubMed Central Open Access</source><creator>McDermid, Joanne ; Henley, William ; Corbett, Anne ; Williams, Gareth ; Fossey, Jane ; Clare, Linda ; Fox, Chris ; Aarsland, Dag ; Khan, Zunera ; Soto, Maria ; Woodward‐Carlton, Barbara ; Cook, Esme Moniz ; Cummings, Jeffrey ; Sweetnam, Adrienne ; Chan, Xavier ; Lawrence, Megan ; Ballard, Clive</creator><creatorcontrib>McDermid, Joanne ; Henley, William ; Corbett, Anne ; Williams, Gareth ; Fossey, Jane ; Clare, Linda ; Fox, Chris ; Aarsland, Dag ; Khan, Zunera ; Soto, Maria ; Woodward‐Carlton, Barbara ; Cook, Esme Moniz ; Cummings, Jeffrey ; Sweetnam, Adrienne ; Chan, Xavier ; Lawrence, Megan ; Ballard, Clive ; iWHELD study group ; the iWHELD study group</creatorcontrib><description>INTRODUCTION
iWHELD is a digital person‐centered care program for people with dementia in nursing homes adapted for remote delivery during the COVID‐19 pandemic.
METHODS
A 16‐week two‐arm cluster‐randomized controlled trial in 149 UK nursing homes compared iWHELD with treatment as usual (TAU). Primary outcome was the overall quality of life with secondary outcomes of agitation and psychotropic use.
RESULTS
iWHELD conferred benefit to quality of life on the primary (F = 4.3, p = 0.04) and secondary measures of quality of life (F = 6.45, p = 0.01) and reduced psychotropic medication use (χ2 = 4.08, p = 0.04) with no worsening of agitation. Benefit was seen in participants who contracted COVID‐19, those with agitation at baseline, and those taking psychotropic medications.
DISCUSSION
iWHELD confers benefits to quality of life and key measures of well‐being, can be delivered during the challenging conditions of a pandemic, and should be considered for use alongside any emerging pharmacological treatment for neuropsychiatric symptoms.
Highlights
iWHELD is the only remote, digital delivery nursing home training programme for dementia care
iWHELD improved quality of life in people with dementia and reduced antipsychotic use without worsening of agitation
Residents who contracted Covid‐19 during the study also experienced benefits from iWHELD
iWHELD offers a valuable, pandemic‐safe tool for improving dementia care</description><identifier>ISSN: 1552-5260</identifier><identifier>ISSN: 1552-5279</identifier><identifier>EISSN: 1552-5279</identifier><identifier>DOI: 10.1002/alz.13582</identifier><identifier>PMID: 38116916</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Aged ; Agitation ; Alzheimer's disease ; Antipsychotics ; Clinical trials ; Coaching ; Collaboration ; Computer platforms ; COVID-19 ; COVID-19 - complications ; Dementia ; Dementia - diagnosis ; digital ; Drugs ; FDA approval ; Homes for the Aged ; Humans ; Intervention ; iWHELD ; Mortality ; Neuropsychiatric symptoms ; nursing home ; Nursing Homes ; Pandemics ; Patient-Centered Care ; person‐centered care ; Psychomotor Agitation - diagnosis ; Psychomotor Agitation - drug therapy ; psychotropic ; Psychotropic drugs ; Quality of Life ; Training ; Treatment methods ; Well being</subject><ispartof>ALZHEIMERS & DEMENTIA, 2024-03, Vol.20 (3), p.1797-1806</ispartof><rights>2023 The Authors. published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</rights><rights>2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</rights><rights>2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4422-d0b463c4bd85425630bc861d4d2b63d042c2232a48a2cc2ec8084cc7a9bd47663</cites><orcidid>0000-0003-2015-0316</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984502/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984502/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,723,776,780,881,1411,11541,12825,27901,27902,30976,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38116916$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:154448106$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>McDermid, Joanne</creatorcontrib><creatorcontrib>Henley, William</creatorcontrib><creatorcontrib>Corbett, Anne</creatorcontrib><creatorcontrib>Williams, Gareth</creatorcontrib><creatorcontrib>Fossey, Jane</creatorcontrib><creatorcontrib>Clare, Linda</creatorcontrib><creatorcontrib>Fox, Chris</creatorcontrib><creatorcontrib>Aarsland, Dag</creatorcontrib><creatorcontrib>Khan, Zunera</creatorcontrib><creatorcontrib>Soto, Maria</creatorcontrib><creatorcontrib>Woodward‐Carlton, Barbara</creatorcontrib><creatorcontrib>Cook, Esme Moniz</creatorcontrib><creatorcontrib>Cummings, Jeffrey</creatorcontrib><creatorcontrib>Sweetnam, Adrienne</creatorcontrib><creatorcontrib>Chan, Xavier</creatorcontrib><creatorcontrib>Lawrence, Megan</creatorcontrib><creatorcontrib>Ballard, Clive</creatorcontrib><creatorcontrib>iWHELD study group</creatorcontrib><creatorcontrib>the iWHELD study group</creatorcontrib><title>Impact of the iWHELD digital person‐centered care program on quality of life, agitation and psychotropic medications in people with dementia living in nursing homes during the COVID‐19 pandemic: A randomized controlled trial</title><title>ALZHEIMERS & DEMENTIA</title><addtitle>Alzheimers Dement</addtitle><description>INTRODUCTION
iWHELD is a digital person‐centered care program for people with dementia in nursing homes adapted for remote delivery during the COVID‐19 pandemic.
METHODS
A 16‐week two‐arm cluster‐randomized controlled trial in 149 UK nursing homes compared iWHELD with treatment as usual (TAU). Primary outcome was the overall quality of life with secondary outcomes of agitation and psychotropic use.
RESULTS
iWHELD conferred benefit to quality of life on the primary (F = 4.3, p = 0.04) and secondary measures of quality of life (F = 6.45, p = 0.01) and reduced psychotropic medication use (χ2 = 4.08, p = 0.04) with no worsening of agitation. Benefit was seen in participants who contracted COVID‐19, those with agitation at baseline, and those taking psychotropic medications.
DISCUSSION
iWHELD confers benefits to quality of life and key measures of well‐being, can be delivered during the challenging conditions of a pandemic, and should be considered for use alongside any emerging pharmacological treatment for neuropsychiatric symptoms.
Highlights
iWHELD is the only remote, digital delivery nursing home training programme for dementia care
iWHELD improved quality of life in people with dementia and reduced antipsychotic use without worsening of agitation
Residents who contracted Covid‐19 during the study also experienced benefits from iWHELD
iWHELD offers a valuable, pandemic‐safe tool for improving dementia care</description><subject>Aged</subject><subject>Agitation</subject><subject>Alzheimer's disease</subject><subject>Antipsychotics</subject><subject>Clinical trials</subject><subject>Coaching</subject><subject>Collaboration</subject><subject>Computer platforms</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>Dementia</subject><subject>Dementia - diagnosis</subject><subject>digital</subject><subject>Drugs</subject><subject>FDA approval</subject><subject>Homes for the Aged</subject><subject>Humans</subject><subject>Intervention</subject><subject>iWHELD</subject><subject>Mortality</subject><subject>Neuropsychiatric symptoms</subject><subject>nursing home</subject><subject>Nursing Homes</subject><subject>Pandemics</subject><subject>Patient-Centered Care</subject><subject>person‐centered care</subject><subject>Psychomotor Agitation - diagnosis</subject><subject>Psychomotor Agitation - drug therapy</subject><subject>psychotropic</subject><subject>Psychotropic drugs</subject><subject>Quality of Life</subject><subject>Training</subject><subject>Treatment methods</subject><subject>Well being</subject><issn>1552-5260</issn><issn>1552-5279</issn><issn>1552-5279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><sourceid>BENPR</sourceid><sourceid>D8T</sourceid><recordid>eNp1Us1uEzEYXCEQLYUDL4AscQGJtLbXu_FyQVFaaKRIvfAjcbG89pfExWtv7d1G6YlH4BkRD4K3SaMWidPOeuabGX36suwlwccEY3oi7c0xyQtOH2WHpCjoqKDj6vEel_ggexbjJcYMc1I8zQ5yTkhZkfIw-zNrWqk65BeoWwEy387P5qdIm6XppEUthOjd75-_FLgOAmikZADUBr8MskHeoateWtNthnlrFvAOyWGyM4mSTqM2btTKd8G3RqEGtFG3XETGJXPfWkBr062QhiYlGJlMro1bDrTrQxzgyjcQke7D8DN0nF58nZ2mTqRCbcqAxqj3aIJCwr4xN0NJ71KktQl2wUj7PHuykDbCi933KPvy8ezz9Hw0v_g0m07mI8UYpSONa1bmitWaF4wWZY5rxUuimaZ1mWvMqKI0p5JxSZWioDjmTKmxrGrNxmWZH2WjrW9cQ9vXog2mkWEjvDRi9_QjIRCcYUxI0n_Y6hOTljMsOUj7YOwh48xKLP21ILjirMA0ObzZOQR_1UPsRGOiAmulA99HQSvMSDGuqiHs9T_SS98Hl_YhcswrXrKcFEn1dqtSwccYYLFvQ7AYjk2kYxO3x5a0r-7X3yvvrisJTraCtbGw-b-TmMy_by3_Aga75V4</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>McDermid, Joanne</creator><creator>Henley, William</creator><creator>Corbett, Anne</creator><creator>Williams, Gareth</creator><creator>Fossey, Jane</creator><creator>Clare, Linda</creator><creator>Fox, Chris</creator><creator>Aarsland, Dag</creator><creator>Khan, Zunera</creator><creator>Soto, Maria</creator><creator>Woodward‐Carlton, Barbara</creator><creator>Cook, Esme Moniz</creator><creator>Cummings, Jeffrey</creator><creator>Sweetnam, Adrienne</creator><creator>Chan, Xavier</creator><creator>Lawrence, Megan</creator><creator>Ballard, Clive</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0003-2015-0316</orcidid></search><sort><creationdate>202403</creationdate><title>Impact of the iWHELD digital person‐centered care program on quality of life, agitation and psychotropic medications in people with dementia living in nursing homes during the COVID‐19 pandemic: A randomized controlled trial</title><author>McDermid, Joanne ; Henley, William ; Corbett, Anne ; Williams, Gareth ; Fossey, Jane ; Clare, Linda ; Fox, Chris ; Aarsland, Dag ; Khan, Zunera ; Soto, Maria ; Woodward‐Carlton, Barbara ; Cook, Esme Moniz ; Cummings, Jeffrey ; Sweetnam, Adrienne ; Chan, Xavier ; Lawrence, Megan ; Ballard, Clive</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4422-d0b463c4bd85425630bc861d4d2b63d042c2232a48a2cc2ec8084cc7a9bd47663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Agitation</topic><topic>Alzheimer's disease</topic><topic>Antipsychotics</topic><topic>Clinical trials</topic><topic>Coaching</topic><topic>Collaboration</topic><topic>Computer platforms</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>Dementia</topic><topic>Dementia - diagnosis</topic><topic>digital</topic><topic>Drugs</topic><topic>FDA approval</topic><topic>Homes for the Aged</topic><topic>Humans</topic><topic>Intervention</topic><topic>iWHELD</topic><topic>Mortality</topic><topic>Neuropsychiatric symptoms</topic><topic>nursing home</topic><topic>Nursing Homes</topic><topic>Pandemics</topic><topic>Patient-Centered Care</topic><topic>person‐centered care</topic><topic>Psychomotor Agitation - diagnosis</topic><topic>Psychomotor Agitation - drug therapy</topic><topic>psychotropic</topic><topic>Psychotropic drugs</topic><topic>Quality of Life</topic><topic>Training</topic><topic>Treatment methods</topic><topic>Well being</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McDermid, Joanne</creatorcontrib><creatorcontrib>Henley, William</creatorcontrib><creatorcontrib>Corbett, Anne</creatorcontrib><creatorcontrib>Williams, Gareth</creatorcontrib><creatorcontrib>Fossey, Jane</creatorcontrib><creatorcontrib>Clare, Linda</creatorcontrib><creatorcontrib>Fox, Chris</creatorcontrib><creatorcontrib>Aarsland, Dag</creatorcontrib><creatorcontrib>Khan, Zunera</creatorcontrib><creatorcontrib>Soto, Maria</creatorcontrib><creatorcontrib>Woodward‐Carlton, Barbara</creatorcontrib><creatorcontrib>Cook, Esme Moniz</creatorcontrib><creatorcontrib>Cummings, Jeffrey</creatorcontrib><creatorcontrib>Sweetnam, Adrienne</creatorcontrib><creatorcontrib>Chan, Xavier</creatorcontrib><creatorcontrib>Lawrence, Megan</creatorcontrib><creatorcontrib>Ballard, Clive</creatorcontrib><creatorcontrib>iWHELD study group</creatorcontrib><creatorcontrib>the iWHELD study group</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>ALZHEIMERS & DEMENTIA</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McDermid, Joanne</au><au>Henley, William</au><au>Corbett, Anne</au><au>Williams, Gareth</au><au>Fossey, Jane</au><au>Clare, Linda</au><au>Fox, Chris</au><au>Aarsland, Dag</au><au>Khan, Zunera</au><au>Soto, Maria</au><au>Woodward‐Carlton, Barbara</au><au>Cook, Esme Moniz</au><au>Cummings, Jeffrey</au><au>Sweetnam, Adrienne</au><au>Chan, Xavier</au><au>Lawrence, Megan</au><au>Ballard, Clive</au><aucorp>iWHELD study group</aucorp><aucorp>the iWHELD study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of the iWHELD digital person‐centered care program on quality of life, agitation and psychotropic medications in people with dementia living in nursing homes during the COVID‐19 pandemic: A randomized controlled trial</atitle><jtitle>ALZHEIMERS & DEMENTIA</jtitle><addtitle>Alzheimers Dement</addtitle><date>2024-03</date><risdate>2024</risdate><volume>20</volume><issue>3</issue><spage>1797</spage><epage>1806</epage><pages>1797-1806</pages><issn>1552-5260</issn><issn>1552-5279</issn><eissn>1552-5279</eissn><abstract>INTRODUCTION
iWHELD is a digital person‐centered care program for people with dementia in nursing homes adapted for remote delivery during the COVID‐19 pandemic.
METHODS
A 16‐week two‐arm cluster‐randomized controlled trial in 149 UK nursing homes compared iWHELD with treatment as usual (TAU). Primary outcome was the overall quality of life with secondary outcomes of agitation and psychotropic use.
RESULTS
iWHELD conferred benefit to quality of life on the primary (F = 4.3, p = 0.04) and secondary measures of quality of life (F = 6.45, p = 0.01) and reduced psychotropic medication use (χ2 = 4.08, p = 0.04) with no worsening of agitation. Benefit was seen in participants who contracted COVID‐19, those with agitation at baseline, and those taking psychotropic medications.
DISCUSSION
iWHELD confers benefits to quality of life and key measures of well‐being, can be delivered during the challenging conditions of a pandemic, and should be considered for use alongside any emerging pharmacological treatment for neuropsychiatric symptoms.
Highlights
iWHELD is the only remote, digital delivery nursing home training programme for dementia care
iWHELD improved quality of life in people with dementia and reduced antipsychotic use without worsening of agitation
Residents who contracted Covid‐19 during the study also experienced benefits from iWHELD
iWHELD offers a valuable, pandemic‐safe tool for improving dementia care</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>38116916</pmid><doi>10.1002/alz.13582</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-2015-0316</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1552-5260 |
| ispartof | ALZHEIMERS & DEMENTIA, 2024-03, Vol.20 (3), p.1797-1806 |
| issn | 1552-5260 1552-5279 1552-5279 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_840011 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Wiley Online Library Open Access; Wiley Online Library Journals Frontfile Complete; PubMed Central; SWEPUB Freely available online; PubMed Central Open Access |
| subjects | Aged Agitation Alzheimer's disease Antipsychotics Clinical trials Coaching Collaboration Computer platforms COVID-19 COVID-19 - complications Dementia Dementia - diagnosis digital Drugs FDA approval Homes for the Aged Humans Intervention iWHELD Mortality Neuropsychiatric symptoms nursing home Nursing Homes Pandemics Patient-Centered Care person‐centered care Psychomotor Agitation - diagnosis Psychomotor Agitation - drug therapy psychotropic Psychotropic drugs Quality of Life Training Treatment methods Well being |
| title | Impact of the iWHELD digital person‐centered care program on quality of life, agitation and psychotropic medications in people with dementia living in nursing homes during the COVID‐19 pandemic: A randomized controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T02%3A56%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20the%20iWHELD%20digital%20person%E2%80%90centered%20care%20program%20on%20quality%20of%20life,%20agitation%20and%20psychotropic%20medications%20in%20people%20with%20dementia%20living%20in%20nursing%20homes%20during%20the%20COVID%E2%80%9019%20pandemic:%20A%20randomized%20controlled%20trial&rft.jtitle=ALZHEIMERS%20&%20DEMENTIA&rft.au=McDermid,%20Joanne&rft.aucorp=iWHELD%20study%20group&rft.date=2024-03&rft.volume=20&rft.issue=3&rft.spage=1797&rft.epage=1806&rft.pages=1797-1806&rft.issn=1552-5260&rft.eissn=1552-5279&rft_id=info:doi/10.1002/alz.13582&rft_dat=%3Cproquest_swepu%3E3089864315%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3089864315&rft_id=info:pmid/38116916&rfr_iscdi=true |